Evaluating the Cardiorenal Benefits of Dapagliflozin and Valsartan in Individuals with Type 2 Diabetes and Hypertension: A Retrospective Cohort Analysis - Takeaways - MDSpire

Evaluating the Cardiorenal Benefits of Dapagliflozin and Valsartan in Individuals with Type 2 Diabetes and Hypertension: A Retrospective Cohort Analysis

  • By

  • Zhengrong Zhou

  • Kaizheng Gong

  • April 24, 2026

  • 0 min

Share

  • 1

    The study evaluated the cardiorenal efficacy of dapagliflozin combined with valsartan in patients with type 2 diabetes and hypertension.

  • 2

    At 24 weeks, the Combination Group showed greater reductions in blood pressure and glycemic parameters compared to valsartan monotherapy.

  • 3

    Inflammatory and cardiac biomarkers declined more significantly in the Combination Group, indicating improved overall health.

  • 4

    Significant improvements in echocardiographic measures and renal function were observed in the Combination Group after 24 weeks.

  • 5

    Combination therapy with dapagliflozin and valsartan independently predicted better cardiorenal outcomes in high-risk patients.

Original Source(s)

Evaluating the Cardiorenal Benefits of Dapagliflozin and Valsartan in Individuals with Type 2 Diabetes and Hypertension: A Retrospective Cohort Analysis

  • by Zhengrong Zhou, Kaizheng Gong

  • April 24, 2026

Related Content

Triangulating evidence for cardiometabolic Index: ROC cutoff, spline nonlinearity, and explainable machine learning for CVD high risk

Dapagliflozin and linagliptin combination therapy improves time in range and reverses hepatic steatosis in patients with type 2 diabetes and hypertension

BMI-specific nonlinear associations and threshold effects of the atherogenic index of plasma on incident prediabetes: insights from 100473 Chinese adults